Oncologix Tech Inc
Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. It offers personal home care services, including daily living assistance, companionship, and homemaker services, as well as Alzheimer's care, home care resource planning, and medical care coordination services. The company also manufactures, markets, and distributes medical technologie… Read more
Oncologix Tech Inc (OCLG) - Net Assets
Latest net assets as of November 2022: $-18.77K USD
Based on the latest financial reports, Oncologix Tech Inc (OCLG) has net assets worth $-18.77K USD as of November 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.85K) and total liabilities ($23.62K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-18.77K |
| % of Total Assets | -387.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 320.77 |
Oncologix Tech Inc - Net Assets Trend (1996–2017)
This chart illustrates how Oncologix Tech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncologix Tech Inc (1996–2017)
The table below shows the annual net assets of Oncologix Tech Inc from 1996 to 2017.
| Year | Net Assets | Change |
|---|---|---|
| 2017-08-31 | $-5.97 Million | -64.88% |
| 2016-08-31 | $-3.62 Million | -98.72% |
| 2015-08-31 | $-1.82 Million | -174.11% |
| 2014-08-31 | $-664.72K | -84.26% |
| 2013-08-31 | $-360.75K | +38.59% |
| 2012-08-31 | $-587.40K | +9.22% |
| 2011-08-31 | $-647.05K | -8.44% |
| 2010-08-31 | $-596.70K | +67.17% |
| 2009-08-31 | $-1.82 Million | +27.18% |
| 2008-08-31 | $-2.50 Million | -23.24% |
| 2007-08-31 | $-2.03 Million | -236.51% |
| 2006-08-31 | $-601.83K | -331.66% |
| 2005-08-31 | $259.79K | -44.49% |
| 2004-08-31 | $467.97K | -90.27% |
| 2003-08-31 | $4.81 Million | -43.10% |
| 2002-08-31 | $8.45 Million | -23.84% |
| 2001-08-31 | $11.10 Million | -18.69% |
| 2000-08-31 | $13.65 Million | +955.78% |
| 1999-08-31 | $1.29 Million | -39.94% |
| 1998-08-31 | $2.15 Million | -0.25% |
| 1997-08-31 | $2.16 Million | -38.51% |
| 1996-08-31 | $3.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncologix Tech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4614347000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.66 Million | 100.00% |
| Other Components | $49.40 Million | 2971.23% |
| Total Equity | $1.66 Million | 100.00% |
Oncologix Tech Inc Competitors by Market Cap
The table below lists competitors of Oncologix Tech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GENWORTH FINANCL-A
BE:GGK
|
$73.74K |
|
HDB Financial Services Limited
NSE:HDBFS
|
$73.85K |
|
Success Hldg Grp
PINK:SHGR
|
$73.86K |
|
BBUG39
SA:BBUG39
|
$73.87K |
|
MITSUBISHI LOGIS
MU:MIB
|
$73.64K |
|
Me Group International PLC
LSE:MEGP
|
$73.62K |
|
Infrastrutture Wireless Italiane SpA
STU:WI8
|
$73.61K |
|
Samhwa Paint Industrial Co. Ltd.
KQ:000390
|
$73.56K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncologix Tech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -6,666,379 to 1,662,469, a change of 8,328,848.
- Other comprehensive income increased equity by 1,544,889.
- Other factors increased equity by 6,783,959.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $0.00 | -0.0% |
| Other Comprehensive Income | $1.54 Million | +92.93% |
| Other Changes | $6.78 Million | +408.07% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Oncologix Tech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-08-31 | $7.52 | $0.00 | x |
| 1997-08-31 | $3.42 | $0.00 | x |
| 1998-08-31 | $3.23 | $0.00 | x |
| 1999-08-31 | $1.78 | $0.00 | x |
| 2000-08-31 | $16.95 | $0.00 | x |
| 2001-08-31 | $4.93 | $0.00 | x |
| 2002-08-31 | $2.12 | $0.00 | x |
| 2003-08-31 | $0.82 | $0.00 | x |
| 2004-08-31 | $0.06 | $0.00 | x |
| 2005-08-31 | $0.02 | $0.00 | x |
| 2006-08-31 | $-0.05 | $0.00 | x |
| 2007-08-31 | $-0.12 | $0.00 | x |
| 2008-08-31 | $-0.12 | $0.00 | x |
| 2009-08-31 | $-0.09 | $0.00 | x |
| 2010-08-31 | $-0.01 | $0.00 | x |
| 2011-08-31 | $-0.01 | $0.00 | x |
| 2012-08-31 | $-0.01 | $0.00 | x |
| 2013-08-31 | $-0.01 | $0.00 | x |
| 2014-08-31 | $-0.01 | $0.00 | x |
| 2015-08-31 | $-0.01 | $0.00 | x |
| 2016-08-31 | $-0.01 | $0.00 | x |
| 2017-08-31 | $-0.01 | $0.00 | x |
| 2019-08-31 | $0.00 | $0.00 | x |
| 2020-08-31 | $0.00 | $0.00 | x |
| 2021-08-31 | $0.00 | $0.00 | x |
| 2022-08-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncologix Tech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -83.19%
- • Asset Turnover: 1.91x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-102.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -53.00% | -9349.08% | 0.00x | 1.31x | $-2.21 Million |
| 1997 | -83.40% | -207.96% | 0.28x | 1.46x | $-2.02 Million |
| 1998 | -56.53% | -771.04% | 0.06x | 1.18x | $-1.43 Million |
| 1999 | -81.20% | -7731.96% | 0.01x | 1.22x | $-1.18 Million |
| 2000 | -21.51% | -10240.67% | 0.00x | 1.02x | $-4.30 Million |
| 2001 | -34.26% | -770.99% | 0.04x | 1.01x | $-4.91 Million |
| 2002 | -65.17% | -519.32% | 0.11x | 1.12x | $-6.36 Million |
| 2003 | -100.43% | -328.42% | 0.26x | 1.19x | $-5.31 Million |
| 2004 | -1453.51% | -314.47% | 2.34x | 1.97x | $-6.85 Million |
| 2005 | -297.94% | -50.06% | 3.37x | 1.77x | $-799.98K |
| 2006 | 0.00% | -518.40% | 1.75x | 0.00x | $-6.03 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.35 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.34 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.41 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-683.67K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-171.64K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-227.61K |
| 2013 | 0.00% | -267.35% | 0.12x | 0.00x | $-617.27K |
| 2014 | 0.00% | -35.68% | 1.72x | 0.00x | $-1.25 Million |
| 2015 | 0.00% | -52.08% | 1.56x | 0.00x | $-2.37 Million |
| 2016 | 0.00% | -46.09% | 1.86x | 0.00x | $-1.49 Million |
| 2017 | 0.00% | -83.19% | 1.91x | 0.00x | $-1.77 Million |
Industry Comparison
This section compares Oncologix Tech Inc's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncologix Tech Inc (OCLG) | $-18.77K | -53.00% | N/A | $73.66K |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |